Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H15N3O2 |
| Molecular Weight | 233.2664 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C2=C3OC(=O)NC3=CC=C2
InChI
InChIKey=YVPUUUDAZYFFQT-UHFFFAOYSA-N
InChI=1S/C12H15N3O2/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9/h2-4H,5-8H2,1H3,(H,13,16)
| Molecular Formula | C12H15N3O2 |
| Molecular Weight | 233.2664 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pardoprunox is a partial D2/3 dopamine receptor agonist and full 5-HT1A serotonin receptor agonist. Partial D(2/3) dopamine (DA) receptor agonists provide a novel approach to the treatment of the motor symptoms of Parkinson's disease that may avoid common dopaminergic side effects, including dyskinesia and psychosis. Pardoprunox passed phase III clinical trial for the treatment of Parkinson's disease.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20434890 |
8.5 null [pKi] | ||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20434890 |
8.1 null [pKi] | ||
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20434890 |
8.6 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | PARDOPRUNOX Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. | 2010-12 |
|
| Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. | 2010-10-15 |
|
| The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders. | 2010-08 |
|
| An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. | 2010-08 |
|
| Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. | 2010-04-30 |
|
| Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. | 2009 |
|
| New frontiers in the pharmacological management of Parkinson's disease. | 2008-07 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20198713
Pardoprunox was titrated to each patient’s optimal dose (9–45 mg/d) over 2 to 6 weeks and then maintained at this dose for a further 3 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17001660
At cloned human dopamine D2 receptors, pardoprunox (SLV308) acted as a potent but partial agonist (pEC50 = 8.0) with an efficacy of 50% on forskolin-stimulated cAMP accumulation. At human recombinant dopamine D3 receptors, SLV308 acted as a partial agonist in the induction of [(35)S]GTPgammaS binding (an intrinsic activity of 67%; pEC50 = 9.2). SLV308 acted as a full 5-HT1A receptor agonist on forskolin-induced cAMP accumulation at cloned human 5-HT1A receptors but with low potency (pEC50 = 6.3).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:29:26 GMT 2025
by
admin
on
Mon Mar 31 18:29:26 GMT 2025
|
| Record UNII |
5R72CHP32S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47794
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
||
|
NCI_THESAURUS |
C66884
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40949747
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
269718-84-5
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
6918525
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
SUB129672
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
Pardoprunox
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
UU-83
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
C80765
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
100000155636
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103832
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
C480679
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
DB12061
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
8727
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY | |||
|
5R72CHP32S
Created by
admin on Mon Mar 31 18:29:26 GMT 2025 , Edited by admin on Mon Mar 31 18:29:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET->PARTIAL AGONIST |
|
||
|
TARGET->PARTIAL AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|